Abstract
Prevalence of the primary drug resistance mutations and resistance developed in patients receiving highly active antiretroviral therapies in the HIV-infected persons in the Privolzhsky federal district was studied. It was demonstrated that among the ART-naive HIV-positive patients there were no mutations leading to the development of resistance. A high level of the resistance to lamivudin, nevirapin, efavirenz was revealed among the persons receiving the antiretroviral therapy. As a whole, the frequency of mutations of resistance to nucleoside reverse transcriptase inhibitors (23.8%) and nonnucleoside reverse transcriptase inhibitors (26.9%) was much higher than to protease inhibitors (1.2%).
MeSH terms
-
Alkynes
-
Antiretroviral Therapy, Highly Active
-
Benzoxazines / therapeutic use*
-
Cyclopropanes
-
Drug Resistance, Viral / drug effects
-
Drug Resistance, Viral / genetics
-
HIV / drug effects
-
HIV / enzymology
-
HIV / genetics*
-
HIV Infections / drug therapy*
-
HIV Infections / virology
-
HIV Protease / genetics
-
HIV Protease Inhibitors / therapeutic use*
-
HIV Reverse Transcriptase / antagonists & inhibitors
-
HIV Reverse Transcriptase / genetics
-
Humans
-
Lamivudine / therapeutic use*
-
Mutation Rate
-
Nevirapine / therapeutic use*
-
Reverse Transcriptase Inhibitors / therapeutic use*
-
Russia
Substances
-
Alkynes
-
Benzoxazines
-
Cyclopropanes
-
HIV Protease Inhibitors
-
Reverse Transcriptase Inhibitors
-
Lamivudine
-
Nevirapine
-
HIV Reverse Transcriptase
-
HIV Protease
-
efavirenz